STOCK TITAN

iSpecimen Reports 129% Year-Over-Year Increase in Third Quarter Revenue; Highlights Completed Orders for Federal Government and the Centers for Disease Control and Prevention (CDC)

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

iSpecimen (ISPC) reported a 129% year-over-year increase in third-quarter 2026 revenue and highlighted completed orders for government and government-affiliated research organizations. Revenue reached approximately $244,000, up from approximately $107,000 a year earlier, as specimen deliveries rose 169% to 752. Cost of revenue fell 55% to approximately $91,000. The company posted gross profit of approximately $153,000, compared with a gross loss of approximately $98,000 a year earlier. Its net loss narrowed to approximately $2.2 million from approximately $2.8 million.

Since 2020, iSpecimen has fulfilled 21 biospecimen orders across nine government and government-affiliated organizations, including projects with the Centers for Disease Control and Prevention. The company continued to receive public-sector inquiries, including requests in 2026.

Loading...
Loading translation...
6 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 1 point

How the balance works

Positive

  • Moderate pointThird-quarter 2026 revenue rose 129% year over year to approximately $244,000 from approximately $107,000
  • Moderate pointThird-quarter gross profit reached approximately $153,000, compared with a gross loss of approximately $98,000 a year earlier
  • Moderate pointThird-quarter specimen deliveries rose 169% to 752 from 280 a year earlier
  • Minor pointThird-quarter cost of revenue fell 55% to approximately $91,000
  • Minor pointAverage cost per specimen fell approximately 83% in the third quarter
  • Minor pointCompleted government and government-affiliated orders totaled 21 across nine organizations since 2020, including the CDC

Negative

  • Major pointThird-quarter net loss was approximately $2.2 million, narrower than approximately $2.8 million a year earlier
Argus 15 min delay 16 alerts
-1.01% vs previous close $0.5277 last price 1.1x rel. volume Open Argus
Details

Market Reaction – ISPC

+16.6% Peak in 4 min
$0.47 – $0.54 Day Range
$3.05M Mkt Cap at Last Price

On Nov 19, the day this news came out, the latest delayed price for ISPC is 1.01% below the previous close. Argus tracked a peak move of +16.6% during the session. Our momentum scanner has recorded 16 alerts for this stock so far that day. The latest delayed price is $0.53.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Revenue: approximately $244,000; increase of 129% Specimens delivered: 752; increase of 169% Cost of revenue: approximately $91,000; decrease of 55% +4 more
Revenue
approximately $244,000; increase of 129%
Third quarter 2026; approximately $107,000 in third quarter 2025
Specimens delivered
752; increase of 169%
Third quarter 2026, compared with 280 in the prior-year quarter
Cost of revenue
approximately $91,000; decrease of 55%
Third quarter 2026
Average cost per specimen
reduction of approximately 83%
Third quarter 2026
Gross profit
approximately $153,000
Third quarter 2026; compared with a gross loss of approximately $98,000 in third quarter 2025
Net loss
approximately $2.2 million
Third quarter 2026; compared with approximately $2.8 million in the prior-year period
Completed biospecimen orders
21 orders across nine organizations
Government and government-affiliated organizations since 2020

Key Terms

biospecimen, cerebrospinal fluid, formalin-fixed paraffin-embedded
3 terms
biospecimen medical
"Company has fulfilled 21 biospecimen orders"
A biospecimen is a biological sample taken from a person, animal, or the environment—such as blood, tissue, saliva, urine, or cells—used for testing, research, or diagnostic development. For investors, biospecimens are the essential raw material for creating drugs, diagnostics and lab tests; their availability, quality, legal consent and proper storage can speed or slow development and directly affect costs, regulatory approval chances and potential market value—like the foundation stones that determine how quickly a building can be completed.
cerebrospinal fluid medical
"including whole blood, serum, cerebrospinal fluid (CSF), urine"
A clear fluid that surrounds and cushions the brain and spinal cord, acting like a protective bath and cleanup system that removes waste and helps circulate nutrients. For investors, cerebrospinal fluid matters because it is a common source of diagnostic markers and a route for delivering or testing neurological drugs; changes in its composition can signal disease or affect a therapy’s development, approval prospects, and market value.
formalin-fixed paraffin-embedded medical
"and formalin-fixed paraffin-embedded (FFPE) tissue"
A laboratory method for preserving and preparing biological tissue samples by first treating them with formalin (a solution of formaldehyde) to fix and stabilize cellular structures, then infiltrating and surrounding the fixed tissue with molten paraffin wax so it can be cut into thin sections for microscopy and archival storage. The formalin step chemically cross-links proteins and preserves tissue morphology, while the paraffin provides physical support; a common limitation is that fixation and embedding can fragment or chemically alter DNA and RNA and mask some molecular or antigenic features, which can affect certain genetic tests and immunoassays.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Company has fulfilled 21 biospecimen orders for federal, state, and government-affiliated research organizations since 2020

Woburn, Massachusetts--(Newsfile Corp. - November 19, 2026) - iSpecimen Inc. (NASDAQ: ISPC), a global marketplace connecting researchers with biospecimens and clinical data, today reported a 129% year-over-year increase in third quarter 2026 revenue and highlighted its experience supporting government and public-sector research through the sourcing and fulfillment of human biospecimens.

Third Quarter 2026 Revenue Growth

Revenue for the third quarter ended September 30, 2026 was approximately $244,000, an increase of 129% from approximately $107,000 in the third quarter of 2025, as reported in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission. The increase was driven mainly by higher customer orders and procurement, with the number of specimens delivered rising 169% to 752 from 280 in the prior-year quarter.

The Company also improved the economics of its fulfillment. Cost of revenue decreased 55% to approximately $91,000, as an approximately 83% reduction in average cost per specimen more than offset the higher volume. As a result, iSpecimen generated gross profit of approximately $153,000 in the quarter, compared with a gross loss of approximately $98,000 in the third quarter of 2025. Net loss narrowed to approximately $2.2 million from approximately $2.8 million in the prior-year period.

Experience Supporting Government Research

Since 2020, iSpecimen has fulfilled 21 biospecimen orders across nine government and government-affiliated organizations, including federal research agencies, national laboratories, and state public health organizations. This work includes previously announced projects with the Centers for Disease Control and Prevention (CDC), as well as additional engagements supporting a range of public-sector research initiatives.

The completed orders have involved at least seven categories of biospecimens, including whole blood, serum, cerebrospinal fluid (CSF), urine, saliva, swabs, and formalin-fixed paraffin-embedded (FFPE) tissue. Projects have supported research spanning infectious disease, public health, oncology, and other areas of biomedical investigation.

These engagements have required access to a range of specimen sources, including established inventories and collections coordinated to meet specific research requirements. Through its network of healthcare institutions, laboratories, and other collection partners, iSpecimen helps researchers identify and access human biospecimens for studies that may otherwise be difficult to source.

"Our third quarter results reflect renewed momentum in customer demand, with revenue more than doubling and specimen volume up 169% from a year ago," said Shahin Behroyan, Chief Executive Officer of iSpecimen. "Our work with the CDC and other government and public-sector organizations shows what our marketplace was built to do: give researchers access to hard-to-source specimens through a network of collection partners that would be difficult to assemble on their own. At the same time, we are fulfilling orders far more efficiently, with a significantly lower cost per specimen, and we see continued opportunity to support government-funded research as we move into 2027."

Continued Engagement and Future Opportunities

In addition to its completed orders, iSpecimen continues to receive inquiries and engage with government and public-sector organizations regarding new research needs. Recent discussions and requests, including activity in 2026, reflect continued interest in accessing diverse human biospecimens through iSpecimen's marketplace.

The Company sees continued opportunity to support government-funded and public-sector research by connecting researchers with its established supplier network and helping coordinate access to specimens across a broad range of collection settings.

About iSpecimen

iSpecimen (NASDAQ: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," "believe," "estimate," "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company's filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in the Company's forward-looking statements.

Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Media Contact

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/324745

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did iSpecimen's third-quarter 2026 revenue grow?

iSpecimen's third-quarter 2026 revenue rose 129% year over year to approximately $244,000 from approximately $107,000. Higher customer orders and procurement drove most of the increase.

How many government research orders has iSpecimen completed?

iSpecimen has fulfilled 21 biospecimen orders since 2020 across nine government and government-affiliated organizations. The completed work includes projects with the Centers for Disease Control and Prevention.

What types of biospecimens did iSpecimen supply for government research?

iSpecimen's completed government and government-affiliated orders covered at least seven biospecimen categories, including whole blood, serum, cerebrospinal fluid, urine, saliva, swabs, and tissue preserved in formalin and embedded in paraffin.

Keep reading